Status:
COMPLETED
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Infection, Human Immunodeficiency Virus I
Eligibility:
All Genders
17+ years
Brief Summary
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg. One case of suspe...
Eligibility Criteria
Inclusion
- New users of DTG or users of other integrase inhibitor regimens (RAL and EGV)
Exclusion
- None
Key Trial Info
Start Date :
September 30 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03327740
Start Date
September 30 2014
End Date
December 31 2019
Last Update
February 6 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.